Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Endocrinology · Type B Insulin Resistance Syndrome

The Path to Remission: The NIH Protocol and Insulin Management

At a Glance

Type B Insulin Resistance Syndrome (TBIRS) is treated with a dual approach. Extremely high doses of concentrated U-500 insulin manage blood sugar, while the NIH Protocol uses immunosuppressants to eliminate the disease-causing antibodies. Sudden hypoglycemia is a critical risk during recovery.

Because Type B Insulin Resistance Syndrome (TBIRS) is both rare and potentially life-threatening, treatment requires a specialized “dual-track” approach. One track focuses on keeping you safe in the short term (glycemic control), while the other targets the root cause of the disease (immunological remission).

Historically, this condition was fatal in about 54% of cases. Today, thanks to standardized protocols, it is considered potentially curable [1].

The NIH (Malek) Protocol

The gold standard for treating the underlying cause of TBIRS is the NIH Protocol, often referred to as the Malek protocol. Unlike typical diabetes treatments, this protocol uses powerful medications to stop your immune system from producing the antibodies that block your insulin receptors [2][1].

This combined approach typically includes:

  • Rituximab: A targeted biological therapy that eliminates the B-cells responsible for making the rogue antibodies [2][3].
  • Cyclophosphamide: An immunosuppressant that helps “reset” the immune system [1].
  • Pulse Dexamethasone: High doses of this potent steroid are given in cycles to rapidly decrease immune activity [2].

Important Context on Immunosuppressants:
It is vital to understand that Rituximab and Cyclophosphamide are heavy-duty medications (often used in chemotherapy or severe autoimmune diseases). They will severely suppress your immune system [2]. While on these drugs, you will be at a high risk for severe infections. You will need to take strict precautions, avoid sick individuals, and immediately report any fevers to your doctor.

Bridging the Gap: High-Dose Insulin

While the immunosuppressive medications take time to work (often weeks or months), your blood sugar must be managed. Because your receptors are blocked, you may require extraordinary doses of insulin—sometimes more than 1,000 units per day [4][5].

To handle these volumes, doctors often use U-500 insulin, which is five times more concentrated than standard insulin (U-100) [6][7].

CRITICAL U-500 SYRINGE WARNING:
Using U-500 insulin requires absolute precision. You must use specific U-500 syringes or a U-500 insulin pen. If you accidentally draw U-500 insulin into a standard U-100 syringe without doing complex conversions, you will inject five times the intended dose, leading to a massive, potentially lethal overdose. Never mix syringe types.

The Transition Phase: Emergency Hypoglycemia Risk

As the NIH protocol begins to clear the antibodies from your system, your insulin receptor autoantibody (IRAb) titers will drop. When this happens, your body will suddenly become sensitive to insulin again [8][9].

This transition is a “danger zone” for severe hypoglycemia. If you are still taking thousands of units of insulin when your receptors suddenly unblock, your blood sugar can crash to life-threatening levels [9]. Using a Continuous Glucose Monitor (CGM) is vital during this phase.

Developing an Emergency Action Plan:
A simple glass of juice will not reverse a crash caused by hundreds of units of insulin. You must develop an explicit emergency action plan with your doctor:

  1. Glucagon Efficacy: Standard rescue treatments (like glucagon kits) may be less effective or insufficient.
  2. Medical Supervision: The ‘Rapid Taper’ of your insulin doses should ideally be done under close, direct medical supervision (often requiring hospitalization or daily contact with your specialist team).
  3. Emergency Room: Know exactly when to go to the ER to receive continuous IV dextrose, as oral glucose may not be enough to combat the massive amounts of active insulin in your system.

Evaluating Your Care Team

TBIRS is so rare that many general practitioners or even some endocrinologists may have never seen a case. Signs of expert care include:

  • They recognize that you need thousands of units of insulin, not just “a little more.”
  • They use the combined NIH Protocol (Rituximab + Cyclophosphamide + Dexamethasone) [1].
  • They involve multiple specialists, such as a Rheumatologist or Clinical Immunologist [10].

The Path to Remission: A Treatment Process Tree

Step 1: Diagnosis & Stabilization↓Start high-dose "Bridge" Insulin (often U-500) to lower blood sugar [4]↓Step 2: The NIH Protocol↓Receive Rituximab, Cyclophosphamide, and Dexamethasone [2]↓Step 3: Monitoring the "Break"↓Antibody (IRAb) levels fall; insulin resistance begins to disappear [8]↓Step 4: Rapid Taper (Requires Close Medical Supervision)↓Aggressively reduce insulin doses to prevent hypoglycemia [9]↓Goal: Remission↓Antibodies undetectable; blood sugar normal without insulin [11] \begin{array}{l} \text{Step 1: Diagnosis \& Stabilization} \\ \downarrow \\ \text{Start high-dose "Bridge" Insulin (often U-500) to lower blood sugar [4]} \\ \downarrow \\ \text{Step 2: The NIH Protocol} \\ \downarrow \\ \text{Receive Rituximab, Cyclophosphamide, and Dexamethasone [2]} \\ \downarrow \\ \text{Step 3: Monitoring the "Break"} \\ \downarrow \\ \text{Antibody (IRAb) levels fall; insulin resistance begins to disappear [8]} \\ \downarrow \\ \text{Step 4: Rapid Taper (Requires Close Medical Supervision)} \\ \downarrow \\ \text{Aggressively reduce insulin doses to prevent hypoglycemia [9]} \\ \downarrow \\ \text{Goal: Remission} \\ \downarrow \\ \text{Antibodies undetectable; blood sugar normal without insulin [11]} \end{array}

Common questions in this guide

What is the NIH Protocol for Type B Insulin Resistance Syndrome?
The NIH Protocol, also known as the Malek protocol, uses a combination of powerful immunosuppressive medications including rituximab, cyclophosphamide, and dexamethasone. These drugs work together to stop your immune system from producing the antibodies that block your insulin receptors.
Why do I need such high doses of insulin for TBIRS?
Because autoantibodies are blocking your insulin receptors, standard amounts of insulin cannot lower your blood sugar. Patients often require massive doses, sometimes over 1,000 units per day using concentrated U-500 insulin, to temporarily overcome this blockage.
What happens when the TBIRS treatment starts working?
As the immunosuppressive medications clear the blocking antibodies, your body will suddenly regain its sensitivity to insulin. If you are still taking massive doses of insulin when this happens, your blood sugar can rapidly drop to life-threatening levels.
How do I manage the risk of severe hypoglycemia during TBIRS recovery?
You must work closely with your medical team to rapidly taper your insulin doses under direct medical supervision. Wearing a continuous glucose monitor (CGM) and having an emergency action plan for IV dextrose administration at the ER is essential.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are we strictly following the NIH (Malek) protocol for my immunosuppressive therapy?
  2. 2.Who is my primary contact for adjusting my insulin dose if I start having sudden drops in blood sugar (hypoglycemia)?
  3. 3.What is our Emergency Action Plan for severe hypoglycemia, and when should I go to the ER or use IV dextrose?
  4. 4.How much experience does this hospital have with administering and managing U-500 concentrated insulin?
  5. 5.What specific infection precautions should I take while on rituximab and cyclophosphamide?
  6. 6.Is a rheumatologist or clinical immunologist co-managing my case along with the endocrinology team?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study.

    Klubo-Gwiezdzinska J, Lange M, Cochran E, et al.

    Diabetes care 2018; (41(11)):2353-2360 doi:10.2337/dc18-0884.

    PMID: 30201849
  2. 2

    Searching for the Culprit: When Diabetic Ketoacidosis Presents With Insulin Autoantibodies.

    Garcia-Avila S, Samuel A, Farooqi I, et al.

    AACE clinical case reports 2021; (7(2)):158-162 doi:10.1016/j.aace.2020.12.004.

    PMID: 34095477
  3. 3

    Diabetic Ketoacidosis Without Diabetes.

    Willard D, Upadhyay J, Kim C, Steenkamp D

    The Journal of clinical endocrinology and metabolism 2016; (101(11)):3870-3873 doi:10.1210/jc.2016-2146.

    PMID: 27636019
  4. 4

    Rare case of type B insulin resistance in association with systemic lupus erythematosus: illustrating diagnostic and management challenges.

    Saqib A, Man Y, Ismail R, Kariyawasam D

    BMJ case reports 2021; (14(8)) doi:10.1136/bcr-2021-242960.

    PMID: 34340988
  5. 5

    Management of a patient with severe insulin resistance.

    Arulanandam B, Garfield N

    JCEM case reports 2026; (4(8)):luag200 doi:10.1210/jcemcr/luag200.

    PMID: 42488373
  6. 6

    Localized insulin amyloidosis with use of concentrated insulin: a potential complication.

    Mangla A, Kim GJ, Agarwal N, et al.

    Diabetic medicine : a journal of the British Diabetic Association 2016; (33(12)):e32-e35 doi:10.1111/dme.13137.

    PMID: 27087031
  7. 7

    Case Series of U-500 Insulin Use in Adults With Type 2 Diabetes and Severe Insulin Resistance.

    Zamora JM, Kong JM

    Canadian journal of diabetes 2021; (45(1)):55-58 doi:10.1016/j.jcjd.2020.05.007.

    PMID: 32847768
  8. 8

    Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy.

    Fujisawa T, Takami K, Horikawa M, et al.

    JCEM case reports 2026; (4(8)):luag181 doi:10.1210/jcemcr/luag181.

    PMID: 42438801
  9. 9

    Early Remission of Type B Insulin Resistance Syndrome Achieved by Glucocorticoid-based Immunosuppressive Therapy and Visualized by Intermittently Scanned Continuous Glucose Monitoring.

    Matsumura-Tojima Y, Sugita T, Tanizaki Y, et al.

    Internal medicine (Tokyo, Japan) 2026; doi:10.2169/internalmedicine.7357-26.

    PMID: 42366039
  10. 10

    Antibody-Mediated Extreme Insulin Resistance: A Report of Three Cases.

    Kim HN, Fesseha B, Anzaldi L, et al.

    The American journal of medicine 2018; (131(1)):102-106 doi:10.1016/j.amjmed.2017.08.004.

    PMID: 28822702
  11. 11

    Long-term remission of type B insulin resistance syndrome with immunotherapy: A case report.

    Egawa E, Karasawa R, Kageyama Y, Takaya K

    Journal of diabetes investigation 2026; (17(3)):542-545 doi:10.1111/jdi.70225.

    PMID: 41451857

This page provides educational information about TBIRS treatment protocols and insulin management. It does not replace professional medical advice. Always consult your endocrinologist and specialized care team regarding your specific treatment plan and emergency protocols.

Get notified when new evidence is published on Insulin-resistance syndrome type B.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.